CA AB1887

Prescription drug coverage for rare diseases.

Engrossed House Rick Zbur (D)
Plain English Summary

CA AB1887 aims to ensure that health insurance plans provide coverage for prescription drugs that treat rare diseases. This legislation seeks to address gaps in health care access for individuals with these conditions, making necessary medications more affordable and available. By adding specific provisions to the Health and Safety Code and Insurance Code, the bill would enhance support for patients facing rare health challenges.

Supporters Say

Supporters of CA AB1887 would highlight that this bill is a crucial step towards equity in healthcare, ensuring that individuals with rare diseases have access to life-saving medications. They would argue that no one should have to choose between their health and financial stability, and this legislation helps to protect vulnerable populations. Advocates believe this bill reflects California's commitment to comprehensive healthcare for all residents.

Critics Say

Critics of CA AB1887 might argue that the bill could increase insurance premiums for all policyholders, as insurers may need to raise rates to cover the costs of mandated prescription drug coverage. They may also contend that the bill could lead to potential overregulation in the health insurance market, stifling innovation and limiting options for consumers. Additionally, some may question the feasibility of implementing such coverage requirements without sufficient funding or resources.

Legislative Votes
Do pass
A · May 14, 2026
Passed
14
YEA
0
NAY
Do pass and be re-referred to the Committee on [Appropriations]
A · Apr 21, 2026
Passed
15
YEA
0
NAY

Source: LegiScan roll call vote data.

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us

About This Analysis

This summary was generated using AI from the bill's official text and metadata. Data sourced from LegiScan and the California State Legislature. Conflict-of-interest analysis for this bill is coming soon.